ArticleWorld journal of surgical oncology2026
Clinical value and regulatory role of lncRNA HOXB-AS3 in gastric cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLncRNA HOXB-AS3 has been shown to exert oncogenic effects in various malignancies. However, its specific role in gastric cancer (GC) remains largely unknown. This study addressed the expression profile and clinical relevance of HOXB-AS3 in GC. Moreover, we dissected its downstream regulatory circuitry in a cell model.
methodsThe cohort comprised 156 GC patients who were followed up for 5 years. Multivariate Cox analysis was employed for risk indicator identification. Relative expression of genes was calculated by RT-qPCR. Cell proliferation was detected by CCK-8 assay, while migration and invasion were assessed by transwell assay. ROC curve was applied for diagnostic efficiency.
resultsHOXB-AS3 was upregulated in GC tissues (P < 0.001) and exhibited promising diagnostic utility (AUC = 0.851, 95% CI: 0.810-0.892). Moreover, high HOXB-AS3 expression positively correlated with poor prognosis (P = 0.005) and was identified as another risk factor (HR = 1.642, 95%CI:1.054-2.557, P = 0.028) besides TNM stage and lymph node metastasis. Mechanistically, HOXB-AS3 overexpression promoted cell proliferation, migration, and invasion through the miR-498-5p/EP300 axis in GC cells.
conclusionsOur findings establish HOXB-AS3 as a potential diagnostic biomarker and therapeutic target in GC, acting via the miR-498-5p/EP300 axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.